---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016997"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T06:31:15.032906+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaxart gets BARDA approval to start dosing 10,000 participants in Phase 2b COVID vaccine trial

## Summary
- BARDA approved initiation of dosing in 10,000-participant Phase 2b trial of oral COVID-19 vaccine.
- First patient expected to be dosed in Q2 2025, per CEO Steven Lo.
- Trial is double-blind, randomized, comparator-controlled vs approved mRNA COVID-19 vaccine.
- Funding under Project NextGen via RRPV Consortium valued at up to $460.7M.
- Funding from HHS/ASPR/BARDA under Other Transaction 75A50123D00005.

## SEC filing metadata
- accession: 0001437749-25-016997
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774925016997/0001437749-25-016997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774925016997/vxrt20250515_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016997
- JSON: https://secwatch.observer/filing/0001437749-25-016997.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016997.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.